$138M | ||
$102M | ||
$95M | ||
$94M | ||
$50M | ||
$43M |
Buys | $0 | 0 | 0 |
Sells | $3,361,221 | 4 | 100 |
Archbold Brian David | SVP Operations | 0 | $0 | 1 | $187,375 | $-187,375 |
Owens Gary M | President and CEO | 0 | $0 | 3 | $3.17M | $-3.17M |
Mesa Laboratories, Inc. develops, manufactures, and sells life sciences tools and quality control products and services in the United States, Europe, the Asia Pacific, and internationally. The company's Sterilization and Disinfection Control segment manufactures and sells biological, cleaning, and chemical indicators that are used to assess the effectiveness of sterilization and disinfection processes in the hospital, dental, medical device, and pharmaceutical industries. This segment also provides testing and laboratory services primarily to the dental industry. Its Biopharmaceutical Development segment develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. This segment's solutions include protein analysis comprising analysis equipment, CDs, kits, and buffers; and peptide synthesizers that enables to automate chemically synthesized peptides that are used in the creation of peptide therapies, biomaterials, cosmetics, and general research. The company's Calibration Solutions segment designs, manufactures, and markets quality control and calibration products to measure or calibrate temperature, pressure, pH, humidity, and other such parameters used for health and safety purposes in the hospital, medical device manufacturing, pharmaceutical manufacturing, and various laboratory and healthcare environments. This segment's products include continuous monitoring systems, dialysate meters and consumables, data loggers, gas flow calibration and air sampling equipment, and torque testing systems. Its Clinical Genomics segment develops, manufactures, and sells genetic analysis tools that include MassARRAY system and consumables, including chips, panels, and chemical reagent solutions used by clinical labs to perform genomic clinical testing in several therapeutic areas, such as newborn screenings, pharmacogenetics, and oncology. The company was incorporated in 1982 and is headquartered in Lakewood, Colorado.
Over the last 12 months, insiders at Mesa Laboratories, Inc. have bought $0 and sold $3.36M worth of Mesa Laboratories, Inc. stock.
On average, over the past 5 years, insiders at Mesa Laboratories, Inc. have bought $100,000 and sold $9.07M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 500 shares for transaction amount of $100,000 was made by Tripeny R Tony () on 2022‑08‑09.
2025-03-19 | Sale | Owens Gary M | President and CEO | 21,000 0.3855% | $123.91 | $2.6M | -5.54% | |
2024-10-29 | Sale | Owens Gary M | President and CEO | 2,551 0.0469% | $111.98 | $285,651 | +12.24% | |
2024-10-28 | Sale | Owens Gary M | President and CEO | 2,518 0.0395% | $113.62 | $286,085 | +12.00% | |
2024-09-13 | Sale | Archbold Brian David | SVP Operations | 1,499 0.0276% | $125.00 | $187,375 | +0.81% | |
2023-12-15 | Sale | Archbold Brian David | SVP Operations | 1,500 0.0282% | $112.36 | $168,540 | -1.59% | |
2023-09-15 | Sale | Schmieder John Bradley | director | 1,000 0.0187% | $123.74 | $123,740 | -15.56% | |
2023-09-14 | Sale | Schmieder John Bradley | director | 3,000 0.0546% | $123.05 | $369,150 | -17.19% | |
2023-09-13 | Sale | Schmieder John Bradley | director | 3,000 0.0559% | $123.32 | $369,965 | -15.24% | |
2023-09-01 | Sale | Owens Gary M | President and CEO | 2,000 0.0378% | $142.82 | $285,640 | -26.10% | |
2023-03-24 | Sale | Sakys John | CFO | 1,128 0.0207% | $167.01 | $188,387 | -33.28% | |
2023-03-22 | Sale | Sakys John | CFO | 2,500 0.0475% | $171.62 | $429,050 | -31.98% | |
2023-03-15 | Sale | Sakys John | CFO | 1,000 0.0185% | $165.71 | $165,710 | -27.37% | |
2023-03-09 | Sale | Sakys John | CFO | 400 0.0074% | $169.97 | $67,988 | -28.54% | |
2023-02-09 | Sale | Sakys John | CFO | 1,000 0.0194% | $184.27 | $184,270 | -28.37% | |
2023-01-23 | Sale | Sakys John | CFO | 2,100 0.0409% | $210.19 | $441,399 | -35.20% | |
2023-01-13 | Sale | Schmieder John Bradley | director | 1,571 0.0295% | $191.31 | $300,548 | -30.17% | |
2022-12-08 | Sale | Hall Shannon | director | 230 0.0042% | $174.97 | $40,244 | -21.32% | |
2022-11-11 | Sale | Schmieder John Bradley | director | 2,500 0.0455% | $175.45 | $438,625 | -12.33% | |
2022-08-18 | Sale | GUILLEMIN EVAN | 3,692 0.0685% | $196.12 | $724,075 | -16.71% | ||
2022-08-16 | Sale | Sakys John | CFO | 1,372 0.0258% | $200.58 | $275,196 | -17.30% |
Owens Gary M | President and CEO | 43337 0.7976% | $5.2M | 0 | 11 | |
Archbold Brian David | SVP Operations | 0 0% | $0 | 0 | 11 | |
SEG Ventures, LLC | director | 200000 3.6808% | $24.02M | 4 | 0 | |
SCHMIEDER LUKE R | director | 172488 3.1745% | $20.72M | 0 | 2 | |
DUKE PAUL D | director | 70043 1.2891% | $8.41M | 0 | 11 | |
Schmieder John Bradley | director | 62760 1.155% | $7.54M | 0 | 18 | |
CAMPBELL H STUART | director | 41527 0.7643% | $4.99M | 1 | 22 | <0.0001% |
Dwyer Robert V | director | 35696 0.6569% | $4.29M | 2 | 26 | |
GUILLEMIN EVAN | 28776 0.5296% | $3.46M | 4 | 19 | ||
BROOKS MICHAEL T | director | 27750 0.5107% | $3.33M | 0 | 4 | |
Sullivan John James | director | 23857 0.4391% | $2.87M | 5 | 35 | |
PETERSON STEVEN W | 21362 0.3931% | $2.57M | 0 | 9 | ||
Adriance Glenn E | CSMO | 10000 0.184% | $1.2M | 1 | 9 | +36.2% |
Sakys John | CFO | 9696 0.1784% | $1.16M | 0 | 29 | |
DINOIA GREGORY | SVP Commercial | 3634 0.0669% | $436,443.40 | 0 | 8 | |
KELLY DAVID M | director | 2600 0.0479% | $312,260.00 | 3 | 14 | +33.14% |
Hall Shannon | director | 957 0.0176% | $114,935.70 | 0 | 1 | |
Tripeny R Tony | 500 0.0092% | $60,050.00 | 1 | 0 | <0.0001% |
Increased Positions | 69 | +38.12% | 608,965 | +12.37% |
Decreased Positions | 75 | -41.44% | 242,220 | -4.92% |
New Positions | 9 | New | 279,329 | New |
Sold Out Positions | 23 | Sold Out | 110,588 | Sold Out |
Total Postitions | 175 | -3.31% | 5M | +7.45% |
Blackrock, Inc. | $98,536.00 | 16.55% | 827,616 | -16,748 | -1.98% | 2025-03-31 |
Conestoga Capital Advisors, Llc | $68,026.00 | 11.43% | 571,358 | -1,679 | -0.29% | 2025-03-31 |
Vanguard Group Inc | $45,583.00 | 7.66% | 382,856 | +5,274 | +1.4% | 2024-12-31 |
Royce & Associates Lp | $34,195.00 | 5.74% | 287,207 | -59,938 | -17.27% | 2024-12-31 |
Raymond James Financial Inc | $29,502.00 | 4.96% | 247,795 | +247,795 | New | 2024-12-31 |
Morgan Stanley | $28,637.00 | 4.81% | 240,526 | -8,822 | -3.54% | 2024-12-31 |
Ranger Investment Management, L.P. | $27,807.00 | 4.67% | 233,555 | -4,635 | -1.95% | 2024-12-31 |
State Street Corp | $26,777.00 | 4.5% | 224,901 | +10,753 | +5.02% | 2024-12-31 |
Geneva Capital Management Llc | $22,504.00 | 3.78% | 189,013 | -2,963 | -1.54% | 2024-12-31 |
Eagle Asset Management Inc | $19,759.00 | 3.32% | 165,955 | +16,293 | +10.89% | 2024-09-30 |